PECU: A multicenter study on pediatric patients with cold‐induced urticaria
Makaleler > Tam Makale · 2026
Yazarlar: Betul Gemici Karaaslan, Ozgen Soyoz, Figen Celebi Celik, Humeyra Akbas, Yakup Canitez, H. Ilbilge Ertoy Karagol, Beril Canan Aksoydan, Yagmur Hazal Sadirvan Oguzkaya, Gizem Uslu, Semiha Bahceci Erdem, Ummugulsum Dikici, Hilal Gungor, Handan DUMAN ŞENOL, Hulya Anil, Adem Yasar, Lida Bulbul, Nursen Cigerci Gunaydin, Ozge Turkyilmaz Ucar, Mehmet Akif Kaya, Sanem Eren Akarcan, Tugba Arikoglu, Ozge Kangalli Boyacioglu, Hatice Eke Gungor, Merve Ocalan, Mahmut Dogru, Mahir Serbes, Nagihan Iskender, Mehmet Kilic, Mutlu Yuksek, Ozlem Yilmaz, Tuba Tuncel, Sefika Ilknur Kokcu Karadag, Zeynep Meric, Tuba Karakurt, Sezin Aydemir, Ugurcan Sayili, Fadil Ozturk, Ozlem Sancakli, Aysen Bingol, Mehmet Halil Celiksoy, Mustafa Atilla Nursoy, Aylin Kont Ozhan, Suna Asilsoy, Ozge Yilmaz, Dilek Ozcan, Isil Eser Simsek, Koray Harmanci, Esen Demir, Deniz Ozceker, Oner Ozdemir, Sukru Cekıc, Mustafa Arga, Ozlem Cavkaytar, Nazli Ercan, Arzu Bakirtas, Zeynep Ulker Altinel, Demet Can, Haluk Cokugras, Esra Yucel, Ayca Kiykim
Pediatric Allergy and Immunology, Uluslararası, Wos, 2026, cilt 37, ss e70379-e70379
DOI: 10.1111/pai.70379
Özet
BACKGROUND: Cold-induced urticaria (ColdU) is a rare chronic inducible urticaria that can cause systemic reactions, including cold-induced anaphylaxis (ColdA), but pediatric data are limited. The aim of this study was to evaluate the clinical characteristics, comorbidities, management approaches, risk of anaphylaxis, and long-term course of ColdU in a pediatric cohort, and to identify risk factors for ColdA, determinants of disease resolution, and predictors of persistence into adulthood. METHODS: This retrospective multicenter study included 203 pediatric patients with ColdU across 30 centers in Türkiye. Clinical characteristics and management of patients were analyzed. Logistic regression was used to identify factors associated with ColdA and disease resolution. RESULTS: The median age at diagnosis was 14.3 years, and the median age at onset was 10 years; 56.1% of patients were female. ColdA occurred in 17.2%, with increased risk associated with male sex, autoimmune comorbidities, older age, and triggering by cold food/beverage ingestion. Most patients (82.2%) received second-generation H1-antihistamines; omalizumab achieved >90% symptom control in 12 refractory cases. Over a median 3.5-year follow-up, 30.5% achieved disease resolution (median duration: 18 months). The history of anaphylaxis and comorbid atopy significantly reduced the likelihood of remission. Some patients showed adult persistence, without clear predictors. DISCUSSION: ColdA may occur even without classic high-risk features; pediatric ColdU management should be guided by individualized risk assessment, prioritizing clinical risk factors-such as older age, high-risk cold triggers, angioedema, and autoimmune comorbidities-over isolated diagnostic parameters. In refractory cases, omalizumab is an effective and well-tolerated option. Prior anaphylaxis and comorbid allergic disease predicted poorer remission.